Gossamer Bio, Chiesi enter seralutinib collaboration

Gossamer Bio and Chiesi Farmaceutici announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib. Under the terms of the agreement, Gossamer will continue to lead global development of seralutinib in PAH and PH-ILD, and the companies will evenly split development costs, except with respect to the PROSERA Study, for which Gossamer will remain financially responsible. In the U.S., the companies will evenly share commercial profits and losses. Gossamer will lead commercialization and book sales for PAH and PH-ILD in the US, with both companies contributing 50% of commercial efforts. Chiesi will lead U.S. commercialization in additional indications. Chiesi will have the exclusive right to commercialize seralutinib outside of the U.S. and will pay Gossamer an escalating mid-to-high teens royalty on net sales. Chiesi will pay Gossamer $160M as a development reimbursement. Additionally, Gossamer will be eligible to receive up to $146M in regulatory milestones and $180M in sales milestones.